Global. Johnson & Johnson improved its sales and profit forecast for the third consecutive quarter. The company's net profit reached $ 5.2 Bln.Johnson & Johnson: BPA $ 1.37 in 3t October 17, 2017 Dow Jones Newswires * Johnson & Johnson: Sales $ 19,700m in 3t * Johnson & Johnson: Adjusted BPA $ 1.90 in 3t * Johnson & Johnson: Net profit US $ 3,760m in 3t J & J improves forecast after achieving 3t profit higher than expected NEW YORK (Dow Jones) - Johnson & Johnson (JNJ) improved its sales and profit forecast for the third consecutive quarter after its pharmaceutical subsidiary contributed to higher-than-expected profit and the highest gain so far of year. Net profit beat expectations of analysts surveyed by Thomson Reuters, reaching $ 5.2 billion in the third quarter. The BPA was US $ 1.90. Experts expected a GPA of US $ 1.8 and a net profit of US $ 4.9 billion. Revenue rose 10% to $ 19.7 billion, surpassing also the analysts' calculations. Revenue from the healthcare giant's pharmaceutical division rose 15% driven by the $ 30 billion purchase of Swiss biotech firm Actelion Ltd. (ATLN.EB) this year, as well as new additions such as the drug Darzalex , for the treatment of multiple myeloma, and cancer therapy. Sales of the company's consumer segment, which includes Tylenol and Neutrogena beauty products, grew only slightly. J & J now expects a adjusted earnings per share for this year of between US $ 7.25 and US $ 7.30, up from the previous estimate of between US $ 7.12 and US $ 7.22. In addition, it revised up its sales forecast to a range between US $ 76.1 billion and US $ 76.5 billion, compared to US $ 75.8 billion and US $ 76.1 billion. The company based in New Brunswick, New Jersey, is the largest seller of health products and is considered a barometer for the industry. Group CEO Alex Gorsky said the company's pharmaceutical business and its recent acquisition of Actelion in particular were the engines of growth. That operation gave the company immediate access to a portfolio of rare disease treatments. -Write Face Lombardo face.lombardo@wsj.com Spanish version of Carlos López Perea carlos.perea@dowjones.comhttp://hogar.intelect.com.mx/notes/global-johnson-johnson-improved-its-sales-and-profit-forecast-for-the-third-consecutive-quarter-the-companys-net-profit-reached-5-2-blnhttp://hogar.intelect.com.mx/@@site-logo/logoAllen.png
Global. Johnson & Johnson improved its sales and profit forecast for the third consecutive quarter. The company's net profit reached $ 5.2 Bln.
Johnson & Johnson: BPA $ 1.37 in 3t October 17, 2017 Dow Jones Newswires * Johnson & Johnson: Sales $ 19,700m in 3t * Johnson & Johnson: Adjusted BPA $ 1.90 in 3t * Johnson & Johnson: Net profit US $ 3,760m in 3t J & J improves forecast after achieving 3t profit higher than expected NEW YORK (Dow Jones) - Johnson & Johnson (JNJ) improved its sales and profit forecast for the third consecutive quarter after its pharmaceutical subsidiary contributed to higher-than-expected profit and the highest gain so far of year. Net profit beat expectations of analysts surveyed by Thomson Reuters, reaching $ 5.2 billion in the third quarter. The BPA was US $ 1.90. Experts expected a GPA of US $ 1.8 and a net profit of US $ 4.9 billion. Revenue rose 10% to $ 19.7 billion, surpassing also the analysts' calculations. Revenue from the healthcare giant's pharmaceutical division rose 15% driven by the $ 30 billion purchase of Swiss biotech firm Actelion Ltd. (ATLN.EB) this year, as well as new additions such as the drug Darzalex , for the treatment of multiple myeloma, and cancer therapy. Sales of the company's consumer segment, which includes Tylenol and Neutrogena beauty products, grew only slightly. J & J now expects a adjusted earnings per share for this year of between US $ 7.25 and US $ 7.30, up from the previous estimate of between US $ 7.12 and US $ 7.22. In addition, it revised up its sales forecast to a range between US $ 76.1 billion and US $ 76.5 billion, compared to US $ 75.8 billion and US $ 76.1 billion. The company based in New Brunswick, New Jersey, is the largest seller of health products and is considered a barometer for the industry. Group CEO Alex Gorsky said the company's pharmaceutical business and its recent acquisition of Actelion in particular were the engines of growth. That operation gave the company immediate access to a portfolio of rare disease treatments. -Write Face Lombardo face.lombardo@wsj.com Spanish version of Carlos López Perea carlos.perea@dowjones.com
Johnson & Johnson: BPA $ 1.37 in 3t
October 17, 2017 Dow Jones Newswires
* Johnson & Johnson: Sales $ 19,700m in 3t
* Johnson & Johnson: Adjusted BPA $ 1.90 in 3t
* Johnson & Johnson: Net profit US $ 3,760m in 3t
J & J improves forecast after achieving 3t profit higher than expected
NEW YORK (Dow Jones) - Johnson & Johnson (JNJ) improved its sales and profit forecast for the third consecutive quarter after its pharmaceutical subsidiary contributed to higher-than-expected profit and the highest gain so far of year.
Net profit beat expectations of analysts surveyed by Thomson Reuters, reaching $ 5.2 billion in the third quarter. The BPA was US $ 1.90.
Experts expected a GPA of US $ 1.8 and a net profit of US $ 4.9 billion.
Revenue rose 10% to $ 19.7 billion, surpassing also the analysts' calculations.
Revenue from the healthcare giant's pharmaceutical division rose 15% driven by the $ 30 billion purchase of Swiss biotech firm Actelion Ltd. (ATLN.EB) this year, as well as new additions such as the drug Darzalex , for the treatment of multiple myeloma, and cancer therapy. Sales of the company's consumer segment, which includes Tylenol and Neutrogena beauty products, grew only slightly.
J & J now expects a adjusted earnings per share for this year of between US $ 7.25 and US $ 7.30, up from the previous estimate of between US $ 7.12 and US $ 7.22. In addition, it revised up its sales forecast to a range between US $ 76.1 billion and US $ 76.5 billion, compared to US $ 75.8 billion and US $ 76.1 billion.
The company based in New Brunswick, New Jersey, is the largest seller of health products and is considered a barometer for the industry.
Group CEO Alex Gorsky said the company's pharmaceutical business and its recent acquisition of Actelion in particular were the engines of growth. That operation gave the company immediate access to a portfolio of rare disease treatments.
-Write Face Lombardo face.lombardo@wsj.com
Spanish version of Carlos López Perea carlos.perea@dowjones.com
